Over 60 companies across the globe claim to manufacture drug products (Roots Analysis)

The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing. <br> <br>To order this 310 page report, which features 110 figures and 200 tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html<br><br>To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html<br><br>Contact Details<br>Gaurav Chaudhary<br> 1 (415) 800 3415<br>gaurav.chaudhary@rootsanalysis.com <br>

kevin987 + Follow